

Physiomics plc
The Magdalen Centre
The Oxford Science Park
Robert Robinson Avenue
Oxford
OX4 4GA
UK

Tel 01865 784980
Fax 08701 671931

24 June 2013

**Physiomics plc
("Physiomics") or ("the Company")**

Physiomics wins poster award at NC3Rs/Society of Biology Symposium 2013

Physiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that it won the second poster prize at the NC3Rs and Society of Biology Symposium held in London on 19 June 2013. The NC3Rs is the National Centre for the Replacement, Refinement & Reduction of Animals in Research.

Dr Eric Fernandez presented a poster on our Virtual Tumour pre-clinical predictive platform. This technology allows experimentalists to prioritise the most effective anti-cancer drug combinations and dramatically reduce the number of animal experiments performed for in vivo validation.

We demonstrated in the poster how the Virtual Tumour could help to reduce by up to 50% the number of animal experiments and accelerate the discovery of optimal drug regimens. A copy of the poster is available on Physiomics website.

Dr Mark Chadwick, CEO of Physiomics, commented:

"We are delighted to be awarded a prize by such a prestigious organization. This highlights the capacity of the Virtual Tumour to reduce both animal use and timelines, saving money for our customers."

Enquiries:

Physiomics plc

Mark Chadwick

+44 (0)1865 784980

WH Ireland Limited

Katy Mitchell

+44 (0) 161 832 2174

About Physiomics plc

Physiomics (AIM:PYC) is a computational systems biology services company applying simulations of cell behaviour to drug development to reduce the high attrition rates of clinical trials. 80-90 per cent of all clinical drug candidates fail to reach the market and estimates show that an overall ten per cent improvement in success rates could reduce the cost of one drug's development by as much as \$242 million, from the current estimate of around \$800 million¹.

Physiomics develops computational systems biology models to predict and understand cancer drug efficacy from pre-clinical research to clinical development. Physiomics has created detailed mathematical models incorporating the most important molecular events taking place during the human cell cycle and apoptosis processes. The company's SystemCell® technology enables the simulation of populations of "virtual cells". The company has also developed a "Virtual Tumour" model to simulate the effect of anti-cancer drugs on tumour growth. The models are used to optimise compound design and to design drug schedules and combination therapies.

Physiomics, based in Oxford, UK, was founded in 2001, and floated on AIM in 2004. For further information, please visit www.physiomics-plc.com

SystemCell® is a registered trademark of Physiomics plc

¹Tufts Centre Impact Report 2002